J&J says its single dose protects against breakthrough COVID-19 for up to 6 months

Johnson & Johnson (JNJ.N) said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.

The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.

Also Read:Johnson and Johnson to split into 2 companies

J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc (PFE.N) and BioNTech's (22UAy.DE) as well as Moderna (MRNA.O).

No waning of protection was found for ICU admissions for all the three vaccines, J&J said.

The company said the study was carried out by collecting claims and laboratory data covering 168 million people.

Also Read:JnJ gets CDSCO panel nod for COVID vaccine study in 12-17 year old